Commodore Capital is a healthcare investment firm based in New York City, specializing in the biopharmaceutical sector. The firm employs a science-driven approach to invest in innovative companies developing medical products aimed at significantly improving patients' lives. Commodore Capital focuses on small-cap public and late-stage private biopharmaceutical companies, particularly those working on genetic medicines and cellular therapies.

The firm strives to be a supportive partner to these companies as they endeavor to bring safe and effective new medicines to patients worldwide.